Check-Cap Reports Fourth Quarter and Full Year 2020 Financial Results

 

Received FDA IDE Approval for Pivotal Study of C-Scan®

 

Company on track to initiate a U.S. pivotal study of C-Scan in late 2021

 

ISFIYA, Israel, March 19, 2021 -- Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan®, the first and only patient-friendly, preparation-free, screening test to detect polyps before they may transform into colorectal cancer (CRC), today announced financial results for the fourth quarter and full year ended December 31, 2020.

 

2020 and Recent Highlights:

 

 

 

 

 

“We ended 2020 optimistically as we look forward to accomplishing our next significant milestone, the commencement of our U.S. pivotal study in late 2021,” said Alex Ovadia, Chief Executive Officer of Check-Cap. “The IDE approval granted by the FDA provides us with the opportunity to demonstrate the clinical efficacy of C-Scan in the U.S., and upon success, to potentially launch our product in the U.S. market,” Mr. Ovadia concluded.

Financial Results for the Fourth Quarter Ended December 31, 2020

 

Research and development expenses, net, were $2.8 million for the three months ended December 31, 2020 and three months ended December 31, 2019. 

 

General and administrative expenses were $1.1 million for the three months ended December 31, 2020, compared to $1.0 million for the same period in 2019. The increase is primarily due to a $0.05 million increase in professional services and $0.05 million increase in salaries and related expenses.

 

Operating loss was $3.9 million for the three months ended December 31, 2020, compared to an operating loss of $3.8 million for the same period in 2019.

 

Finance income, net was $24,000 for the three months ended December 31, 2020, compared to $19,000 for the same period in 2019.

 

Net loss was $3.9 million for the three months ended December 31, 2020, compared to $3.8 million for the same period in 2019.

 

Cash and cash equivalents, restricted cash and short-term bank deposits as of December 31, 2020 were $18.1 million as compared to $8.0 million as of December 31, 2019. Subsequent to the end of the fourth quarter, in the first quarter of 2021, certain existing warrant holders exercised warrants to purchase an aggregate 24,204,682 ordinary shares, which had been issued in 2020, at exercise prices ranging from $0.75-$0.80, which generated total gross proceeds of approximately $19.2 million to the Company.

 

The number of outstanding ordinary shares as of December 31, 2020 was 46,239,183. As of March 16, 2021, the number of outstanding ordinary shares was 70,448,422.

 

Financial Results for the Twelve Months Ended December 31, 2020

 

Research and development expenses, net, were $10.0 million for the twelve months ended December 31, 2020, compared to $10.5 million for the same period in 2019. The decrease is primarily due to (i) a decrease of approximately $0.7 million in clinical expenses mainly due to higher expenses for the pilot study in the U.S and post CE study in 2019 (ii) a decrease of approximately $0.4 million in other research and development expenses, (iii) a decrease of approximately $0.3 million in share-based compensation. The foregoing decrease was offset in part by an increase of approximately $0.8 million in salaries and related expenses mainly as a result of an expansion in head count and currency exchange rate fluctuation.  The decrease in research and development expenses, net between 2020 and 2019 also includes a $0.1 million decrease in grants received from the Israel Innovation Authority.

 

General and administrative expenses were $3.9 million for the twelve months ended December 31, 2020, compared to $3.6 million for the same period in 2019. The increase in general and administrative expenses is primarily due to a $0.2 million increase in salaries and related expenses, $0.1 million increase in share-based compensation expenses and $0.2 million increase in other general expenses, offset by a $0.2 million decrease in professional services expenses.

 

Operating loss was $13.9 million for the twelve months ended December 31, 2020, compared to $14.1 million in the same period in 2019.

 

Finance income, net, was $86,000 for the twelve months ended December 31, 2020, compared to $233,000 for the same period in 2019. The decrease in finance income, net is primarily due to a decrease of $176,000 of interest income of short-term deposits recorded for the year ended December 31, 2020, as compared to the year ended December 31, 2019.

 

Net loss was $13.8 million for the twelve months ended December 31, 2020 and for the twelve months ended December 31, 2019.

 

Net cash used in operating activities was $13.1 million for the twelve months ended December 31, 2020, compared to $12.8 million for the same period in 2019.

 

A copy of the Company’s annual report on Form 20-F for the year ended December 31, 2020 has been filed with the U.S. Securities and Exchange Commission at www.sec.gov and posted on the Company’s investor relations website at  http://ir.check-cap.com/home. The Company will deliver a hard copy of its annual report, including its complete audited consolidated financial statements, free of charge, to its shareholders upon request to Mira Rosenzweig, Chief Financial Officer, at mira.rosenzweig@check-cap.com.

 

About Check-Cap

 

Check-Cap is a clinical stage medical diagnostics company aiming to redefine colorectal cancer (CRC) screening through the introduction of C-Scan®, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into colorectal cancer to enable early intervention and cancer prevention. The Company’s disruptive capsule-based screening technology aims to significantly increase screening adherence worldwide and help millions of people to stay healthy through preventive CRC screening. C-Scan uses an ultra-low dose X-ray capsule, an integrated positioning, control and recording system, as well as proprietary software to generate a 3D map of the inner lining of the colon as it travels naturally along the gastrointestinal tract. C-Scan is non-invasive and requires no sedation. Unlike other capsule technologies, it requires no bowel preparation, allowing the patients to continue their daily routine with no interruption.  C-Scan is not intended to replace colonoscopy. A positive C-Scan result should be followed by colonoscopy.

 

Legal Notice Regarding Forward-Looking Statements

 

This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F for the year ended December 31, 2020 and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

 

Investor Contacts

 

Irina Koffler 
LifeSci Advisors, LLC 
646.970.4681
ikoffler@lifesciadvisors.com

 

Meirav Gomeh-Bauer
LifeSci Advisors, LLC 
+972(0)-54-476-4979
Meirav@lifesciadvisors.com

 

Media Contact

 

Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
mroucomolina@lifescicomms.com